An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

NCT04671849 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

Interventions

DRUG: SIM1803-1A

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.